Aravax

Melbourne, AU · 1 known investors

Aravax develops immunotherapies using proprietary peptides to treat food allergies, with a focus on retraining the immune system to tolerate specific foods. The company's lead product, PVX108, is in Phase 2 clinical trials for peanut allergy treatment in children and adolescents across the United States and Australia.